Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 2/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.33 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2952155 | 0.77 | CDK8 (0.50) | EGFRLTB4RLTB4R2 | |
| SCHEMBL4464529 | 0.69 | CDK8 (0.48) | ATMLTB4RLTB4R2 | |
| SCHEMBL2943838 | 0.65 | CYP1A2 (0.50) | KDM4EEGFRKMT2A | |
| SCHEMBL4603322 | 0.65 | CA1 (0.49) | CYP2C8EGFRRXRAKMT2A | |
| SCHEMBL30719082 | 0.64 | CYP2C8 (0.52) | SRD5A2CYP2C8FOLH1EGFRRXRA | |
| SCHEMBL29788180 | 0.64 | CA1 (0.51) | CYP2C8EGFRRXRAKMT2A | |
| SCHEMBL2044179 | 0.64 | CA1 (0.51) | CYP2C8EGFRRXRAKMT2A | |
| SCHEMBL29152929 | 0.64 | CYP2C8 (0.52) | SRD5A2CYP2C8FOLH1EGFRRXRA | |
| SCHEMBL2949356 | 0.64 | ADRB1 (0.51) | SRD5A2FOLH1EGFRLTB4RRXRA | |
| SCHEMBL930476 | 0.62 | CYP2C8 (0.42) | SRD5A2KDM4ECYP2C8FOLH1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504512-B2 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2009-03-17 | — | — | US | disclosed |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | ABBVIE INC. | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | SRD5A2 2301/4885FFAR4 3401/4885KDM4E 1911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.